Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose open-label mass balance and pharmacokinetics study of 14C-leniolisib in healthy male subjects
NL-OMON50412Completed
- Sponsor
- Pharming Group
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS), sponsored by Pharming Group. Primary endpoint: Total recovery and relative excretion of radioactivity. Started Oct 2021; status: completed.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)
Beyond the preview
Go deeper on NL-OMON50412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50412.